Short answer
Revvity (RVTY) filed its fiscal 2024 10-K annual report with the SEC on Feb 25, 2025. It reported revenue of $2.8B (+0.2% year over year) and net income of $270M.
- Top risk flagged: IRS audit and uncertain tax positions in foreign jurisdictions, with a $33.2 million increase in tax reserves in 2023
FY2024 key financial metrics · XBRL
- Revenue
- $2.8B
- +0.2% YoY
- Net income
- $270M
- −61.0% YoY
- Operating margin
- 12.6%
- +1.7 pp YoY
- EPS (diluted)
- $2.20
- −60.4% YoY
- ROE
- 3.5%
- −5.3 pp YoY
- Operating cash flow
- $628M
- +588.4% YoY
Source: XBRL data from the Revvity (RVTY) FY2024 10-K on SEC EDGAR. USD.
Revvity FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: health science solutions delivering end-to-end workflows from discovery to diagnosis across Life Sciences and Diagnostics segments
- New products FY 2024: BioLegend's TotalSeq™ PhenoCyte™ for scalable single-cell protein analysis; Cellometer™ Ascend automated cell counter; Phenologic.AI™ deep-learning software module
- Strategic emphasis on broadening product portfolio via internal R&D and acquisitions, with focus on translational multi-omics, gene therapy reagents, and diagnostic genomics
- Employee count approx. 11,000 as of Dec 29, 2024; global market reach in 160+ countries; S&P 500 component under ticker "RVTY"
- Noteworthy diagnostic innovation: Ultrarapid Whole Genome Sequencing test delivering NICU results in as fast as five days
Management Discussion & Analysis
- Cash flow, capital allocation figures including buybacks, dividends, capex not stated
- Forward-looking statements caution with no specific guidance or emerging risks detailed
Risk Factors
- IRS audit and uncertain tax positions in foreign jurisdictions, with a $33.2 million increase in tax reserves in 2023
- Ongoing foreign exchange risk, including a $24.0 million loss in 2023 cash proceeds held offshore
- Supply chain and product mix shifts causing 16 basis point gross margin decline and $6.5 million higher cost of revenue in 2024
- Market share pressure from applied genomics segment revenue decline by $23.7 million in 2024 despite growth in immunodiagnostics
- Debt repayment risk from $711.5 million senior unsecured notes paid in 2024, with $1.5 billion revolving credit facility renewal through 2030
Generated from the filing text; verify against the original. How to read a 10-K
Other Revvity annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.